Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2103-2109

  Steller, Michael A ^a,e   Gurski, Karen J ^a   Murakami, Masaru ^a   Daniel, Richard W ^b   Shah, Keerti V ^b   Celis, Esteban ^c   Sette, Alessandro ^c   Trimble, Edward L ^a   Park, Robert C ^d   Marincola, Francesco M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CYTEL CORPORATION   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; HUMAN PAPILLOMAVIRUS 16 E7 VACCINE; LIPOPEPTIDE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE; HLA SYSTEM; HUMAN; IMMUNIZATION; LEUKAPHERESIS; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VAGINA CANCER; WART VIRUS;

ADULT; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; EPITOPES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; LIPIDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, VIRAL; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS;

EID: 0031712034     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 47: 68, 1997]. CA Cancer J. Clin., 47: 5-27, 1997.
2. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J. Natl. Cancer Inst., 87: 796-802, 1995.
3. Munger, K., Scheffner, M., Huibregtse, J. M., and Howley, P. M. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv., 12: 197-217, 1992.
4. Crook, T., Morgenstern, J. P., Crawford, L., and Banks, L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J., 8: 513-519, 1989.
5. Nasiell, K., Roger, V., and Nasiell, M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet. Gynecol., 67: 665-669, 1986.
6. Shamanin, V., Glover, M., Rausch, C., Proby, C., Leigh, I. M., zur Hausen, H., and de Villiers, E. M. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res., 54: 4610-4613, 1994.
7. Maiman, M., Fruchter, R. G., Serur, E., Remy, J. C., Feuer, G., and Boyce, J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol. Oncol., 38: 377-382, 1990.
8. Deres, K., Schild, H., Wiesmuller, K. H., Jung, G., and Rammensee, H. G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine [see comments]. Nature (Lond.), 342: 561-564, 1989.
9. Schild, H., Deres, K., Wiesmuller, K. H., Jung, G., and Rammensee, H. G. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur. J. Immunol., 21: 2649-2654, 1991.
10. Nardelli, B., and Tam, J. P. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology, 79: 355-361, 1993.
11. Carbone, F. R., and Bevan, M. J. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J. Exp. Med., 169: 603-612, 1989.
12. Townsend, A. R., Gotch, F. M., and Davey, J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell, 42: 457-467, 1985.
13. Bastin, J., Rothbard, J., Davey, J., Jones, I., and Townsend, A. Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes. J. Exp. Med., 165: 1508-1523, 1987.
14. Gomard, E., Begue, B., Sodoyer, S., Maryanski, J. L., Jordan, B. R., and Levy, J. P. Murine cells expressing an HLA molecule are specifically lysed by HLA-restricted antiviral human T cells. Nature (Lond.), 319: 153-154, 1986.
15. Maryanski, J. L., Pala, P., Corradin, G., Jordan, B. R., and Cerottini, J. C. H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature (Lond.), 324: 578-579, 1986.
16. Kast, W. M., Brandt, R. M., Drijfhout, J. W., and Melief, C. J. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J. Immunother., 14: 115-120, 1993.
17. Ressing, M. E., Sette, A., Brandt, R. M., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J., and Kast, W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol., 154: 5934-5943, 1995.
18. Alexander, M., Salgaller, M. L., Celis, E., Sette, A., Barnes, W. A., Rosenberg, S. A., and Steller, M. A. Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic HPV-16 E7 epitope. Am. J. Obstet. Gynecol., 175: 1586-1593, 1996.
19. Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., and zur Hausen, H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (Lond.), 314: 111-114, 1985.
20. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., and Sette, A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity, 1: 751-761, 1994.
21. del Guercio, M. F., Alexander, J., Kubo, R. T., Arrhenius, T., Maewal, A., Appella, E., Hoffman, S. L., Jones, T., Valmori, D., Sakaguchi, K., Grey, H. M., and Sette, A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine, 15: 441-448, 1997.
22. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., and Bartholomeuz, R. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest., 95: 341-349, 1995.
23. U. S. Department of Health and Human Services Investigator's Handbook, NIH Publication #2770. Bethesda, MD, 1993.
24. Marincola, F. M., Shamamian, P., Alexander, R. B., Gnarra, J. R., Turetskaya, R. L., Nedospasov, S. A., Simonis, T. B., Taubenberger, J. K., Yannelli, J., and Mixon, A. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol., 153: 1225-1237, 1994.
25. Player, M. A., Barracchini, K. C., Simonis, T. B., Rivoltini, L., Arienti, F., Castelli, C., Mazzocchi, A., Belli, F., Parmiani, G., and Marincola, F. M. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. Emphasis Tumor Immunol., 19: 357-363, 1996.
26. Bauer, H. M., Greer, C. E., and Manos, M. M. Determination of genital HPV infection using consensus PCR. In: C. S. Herrington and J. McGee (eds.), Diagnostic Molecular Pathology: A Practical Approach, pp. 131-152. Oxford, United Kingdom: Oxford University Press, 1992.
27. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
28. Cerundolo, V., Alexander, J., Anderson, K., Lamb, C., Cresswell, P., McMichael, A., Gotch, F., and Townsend, A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (Lond.), 345: 449-452, 1990.
29. Wei, M. L., and Cresswell, P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides [see comments]. Nature (Lond.), 356: 443-446, 1992.
30. Lee, T. D. Distribution of HLA antigens in North American Caucasians, North American blacks and orientals. In: J. Lee (ed.), The HLA System: a New Approach, pp. 141-178. Springer-Verlag: New York, 1990.
31. Jochmus, I., Osen, W., Altmann, A., Buck, G., Hofmann, B., Schneider, A., Gissmann, L., and Rammensee, H. G. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide. J. Gen. Virol., 78: 1689-1695, 1997.
32. Evans, C., Bauer, S., Grubert, T., Brucker, C., Baur, S., Heeg, K., Wagner, H., and Lipford, G. B. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol. Immunother., 42: 151-160, 1996.
33. Karlsen, F., Kalantari, M., Chitemerere, M., Johansson, B., and Hagmar, B. Modifications of human and viral deoxyribonucleic acid by formaldehyde fixation. Lab. Invest., 71: 604-611, 1994.
34. Salgaller, M. L., Marincola, F. M., Cormier, J. N., and Rosenberg, S. A. Immunization against epitopes in the human melanoma antigen gplOO following patient immunization with synthetic peptides. Cancer Res., 56: 4749-4757, 1996.
35. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sci Am., 3: 37-44, 1997.
36. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, M. P., Hartman, M., Anholts, J. D., Schreuder, G. M., ter Harmsel, W. B., Fleuren, G. J., Trimbos, B. J., Kast, W. M., and Melief, C. J. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res., 56: 582-588, 1996.
37. Rivoltini, L., Loftus, D. J., Barracchini, K., Arienti, F., Mazzocchi, A., Biddison, W. E., Salgaller, M. L., Appella, E., Parmiani, G., and Marincola, F. M. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J. Immunol., 156: 3882-3891, 1996.
38. Fleischhauer, K., Tanzarella, S., Russo, V., Sensi, M. L., van der Bruggen, P., Bordignon, C., and Traversari, C. Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J. Immunol., 159: 2513-2521, 1997.
39. Krausa, P., Brywka, M., III, Savage, D., Hui, K. M., Bunce, M., Ngai, J. L., Teo, D. L., Ong, Y. W., Barouch, D., and Allsop, C. E. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens, 45: 223-231, 1995.
40. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W., Westmorland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet, 347: 1523-1527, 1996.